Shop by Category

  • Services
  • ADC and Other Drug Conjugates (ODC)
  • AqT® Reagents and Kits
  • Standards and Controls
  • Biotin and Streptavidin/Avidin
  • Enzyme
  • Antibody
  • Nucleic Acid and Oligo
  • Peptide and Protein
  • Small Molecule
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit®
  • SepSphere™
  • AqT®
  • oxLink™
  • sxLink™
  • View all Brands

    • Investing

    CellMosaic Establishment in 2008

    Established in 2008, CellMosaic is a leader in innovative bioconjugation and drug delivery solutions.

    Unlike traditional biotech investments that bet on single drug candidates, CellMosaic generates revenue throughout the drug development process. Our technology platform serves as the foundation for multiple potential breakthroughs, diversifying risk while maximizing potential returns.

    CellMosaic missionOur mission is to empower researchers and developers with high-quality, advanced bioconjugates that accelerate discovery and therapeutic innovation.

      Key Points:

        • Revenue-generating biotech company with $7.9M+ in lifetime sales and 560+ global customers (as of Nov 9, 2025)
        • Department of Defense-validated platform technology with 13 issued patents and 350+ proprietary processes
        • Operating in a $595B+ global biotech reagents and kits market, with strong growth potential
        • Positioned within the $40B+ ADC market and saw a 400% increase in deal values between 2017-2022
        • Addressing a $200B+ total market opportunity across oncology, diabetes, and other therapeutic areas 

      Building a Complete Research Toolkit

      We've developed several integrated platforms to support different aspects of drug development:

      AqT® Platform (Partialy supported by the DOD Breast Cancer Breakthrough Award) 

        • Enables the development of innovative, high-quality bioconjugation reagents for all aspects of life science research and drug development

        • Supports the creation of high effective, low-toxicity targeted therapies

        • Designed for scalability — from standard research laboratories to AqT® therapeutics manufacturing

      AqT Technologies

      Advanced Conjugation Processes Platform

        • Delivers high-quality, reproducible bioconjugates and high sensitive diagnostic reagents 

        • Seamlessly scalable — from early research to full-scale manufacturing

        • Designed for versatility, supporting applications across life science research and therapeutic production

      CellMosaic Advanced Conjugation Processes

       

      PerKit™ Platform

        • Enables efficient, cost-effective development of targeted therapies

        • Designed for use in standard research labs

        • Scalable from early research to manufacturing

      OxLink™ and SxLink™ Platforms (Supported by NIH SBIR grant)

        • Analyze protein-protein interactions

        • Support target validation

        • Enable binding strength quantification

      NeIon™ Platform

        • Tracks drug metabolites

        • Enhances detection sensitivity

        • Supports pharmacokinetic studies

      products.png

      Real-World Applications

      Our tools are currently supporting research across multiple therapeutic areas:

      Cancer Treatment: Massachusetts General Brigham (MGB) and the German Cancer Research Center (DKFZ) use our technology for specialized drug development programs. IBEX Biosciences employs our platforms for complex bioconjugation in cancer medicine development.

      Addiction Treatment: The University of New Mexico is using our technology in NIH-funded vaccine development for opioid addiction, demonstrating applications beyond oncology (Vaccines2024,2(3), 471-480; NPJ Vaccines 2025, 2025 Mar 28;10(1):57. doi: 10.1038/s41541-025-01105-0)

      Beyond Medicine: Our technology has found applications in unexpected areas, such as food safety testing at Reveal Foods, showing the versatility of our platforms.

      Impact on Drug Development

      Researchers using our platforms have already generated new ADC lead products in various tumor types and reported several advantages:

          • Reduced development time

          • Enhanced targeting efficiency

          • Simplified scale-up processes

      These benefits translate directly to research outcomes. For example, MGB researchers were able to quickly validate their antibody in an ADC system with anti-metastatic activity in breast and pancreatic cancer mouse models, mediating a reduction in circulating tumor cells in the blood, without detectable, obvious toxicity to the mice or to normal tissues. Current ADCs primarily target solid tumors. Their ADC system may become the first few ADCs to specifically target circulating tumor cells to prevent further tumor cell disseminatioin (PNAS 2022, 43 (119), e2209563119). 

      Looking Forward

      The drug delivery landscape is evolving rapidly. The global biotech reagents and kits market is valued at over $595 billion, while the antibody–drug conjugate (ADC) market alone is projected to reach $40 billion by 2029. Broader drug delivery applications represent an additional $200+ billion opportunity.

      CellMosaic is strategically positioned at the intersection of these expanding markets. Having already generated $7.9 million in revenue from a diverse global customer base, we are building on a systematic, scalable approach that ensures our customers and partners can access the most suitable products, services, and technologies for their needs and budgets.

      As we move forward, CellMosaic is poised to accelerate growth, expand its technology footprint, and play a leading role in shaping the future of targeted drug delivery and precision bioconjugation.